Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Proc Natl Acad Sci U S A ; 113(52): E8433-E8442, 2016 12 27.
Article de Anglais | MEDLINE | ID: mdl-27956623

RÉSUMÉ

Mutations in the p53 tumor suppressor gene are the most frequent genetic alteration in cancer and are often associated with progression from benign to invasive stages with metastatic potential. Mutations inactivate tumor suppression by p53, and some endow the protein with novel gain of function (GOF) properties that actively promote tumor progression and metastasis. By comparative gene expression profiling of p53-mutated and p53-depleted cancer cells, we identified ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5) as a mutant p53 target gene, which functions as a uridine 5'-diphosphatase (UDPase) in the endoplasmic reticulum (ER) to promote the folding of N-glycosylated membrane proteins. A comprehensive pan-cancer analysis revealed a highly significant correlation between p53 GOF mutations and ENTPD5 expression. Mechanistically, mutp53 is recruited by Sp1 to the ENTPD5 core promoter to induce its expression. We show ENTPD5 to be a mediator of mutant p53 GOF activity in clonogenic growth, architectural tissue remodeling, migration, invasion, and lung colonization in an experimental metastasis mouse model. Our study reveals folding of N-glycosylated membrane proteins in the ER as a mechanism underlying the metastatic progression of tumors with mutp53 that could provide new possibilities for cancer treatment.


Sujet(s)
Réticulum endoplasmique/métabolisme , Métastase tumorale , Protéines oncogènes/métabolisme , Pyrophosphatases/métabolisme , Protéine p53 suppresseur de tumeur/génétique , Protéine p53 suppresseur de tumeur/physiologie , Animaux , Apoptose , Calnexine/métabolisme , Calréticuline/métabolisme , Carcinogenèse/métabolisme , Lignée cellulaire tumorale , Évolution de la maladie , Femelle , Glycoprotéines/métabolisme , Glycosylation , Humains , Mâle , Souris , Protéines mutantes/génétique , Protéines mutantes/physiologie , Mutation , Invasion tumorale , Pronostic , Interférence par ARN , Petit ARN interférent/métabolisme , Facteur de transcription Sp1/métabolisme
2.
Oral Oncol ; 45(10): e140-9, 2009 Oct.
Article de Anglais | MEDLINE | ID: mdl-19502098

RÉSUMÉ

The peptidyl-prolyl cis/trans isomerase Pin1 has been implicated in malignant transformation in multiple studies, however, little is known about its potential impact in head and neck cancer. This study evaluates the role of Pin1 in head and neck squamous cell carcinomas (HNSCCs). Pin1 expression and level of phosphorylation was evaluated by Western blot analysis and 2D-gel-electrophoresis. Pin1 was inhibited with juglone (5-hydroxy-1,4-naphthalenedione) or Pin1 specific siRNA and its influence on cell cycle checkpoint distribution was assessed by FACS analysis. Pin1 overexpression was found in HNSCC tissues and cell lines. 2D-gel-electrophoresis data pointed to Pin1 being hypophosphorylated in HNSCC cells which is consistent with overactivation of this rotamase. Inhibition of HNSCC cells with juglone or Pin1 siRNA induced the cell cycle inhibitor p21(WAF1/Cip1) with a concomitant reduction of cells in G2/M and an increased fraction of cells with fragmented DNA. Cell death did not correlate with significant levels of apoptosis in Pin1 depleted HNSCC cells. In summary, the data shows that Pin1 is overexpressed and hypophosphorylated in HNSCC, and that inhibition of Pin1 blocks cell cycle progression and triggers tumor cell death. Pin1 therefore could represent a new target for the development of improved HNSCC targeting drugs.


Sujet(s)
Carcinome épidermoïde/métabolisme , Tumeurs de la tête et du cou/métabolisme , Protéines tumorales/métabolisme , Peptidylpropyl isomerase/métabolisme , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Phosphatase alcaline/pharmacologie , Apoptose , Technique de Western , Études cas-témoins , Cycle cellulaire/physiologie , Prolifération cellulaire , Inhibiteur p21 de kinase cycline-dépendante/métabolisme , Électrophorèse bidimensionnelle sur gel , Antienzymes/pharmacologie , Femelle , Humains , Mâle , Adulte d'âge moyen , NIMA-interacting peptidylprolyl isomerase , Naphtoquinones/pharmacologie , Peptidylpropyl isomerase/antagonistes et inhibiteurs , Phosphorylation , Petit ARN interférent/pharmacologie , Régulation positive
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE